Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 31

Results For "Phase-II"

537 News Found

Steps taken by India for preparedness against future pandemics
Policy | July 29, 2024

Steps taken by India for preparedness against future pandemics

Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting


New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Clinical Trials | July 22, 2024

New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions

Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant


GSK and CureVac restructure collaboration into new licensing agreement
News | July 05, 2024

GSK and CureVac restructure collaboration into new licensing agreement

CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced


Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
Drug Approval | July 03, 2024

Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention

Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population


Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer
Drug Approval | July 02, 2024

Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer

Imfinzi also recommended for patients with mismatch repair deficient disease


Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
Drug Approval | June 26, 2024

Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care


Imfinzi improved event-free survival and overall survival for bladder cancer
Clinical Trials | June 26, 2024

Imfinzi improved event-free survival and overall survival for bladder cancer

First immunotherapy regimen before and after surgery to extend survival in bladder cancer


Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer
News | June 22, 2024

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population


Imfinzi approved in the US for endometrial cancer
Drug Approval | June 17, 2024

Imfinzi approved in the US for endometrial cancer

Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy


Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%
Clinical Trials | June 17, 2024

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%

First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting